UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 FORM 6-K 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2019

 

Commission File Number: 001-38764 

 

Aptorum Group Limited 

  

17^th Floor, Guangdong Investment Tower

148 Connaught Road Central

Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒            Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

From March 14-19, 2019, Aptorum Group Limited will participate in a healthcare conference in Miami, Florida. We are attaching a copy of the PowerPoint presentation that the Company will use at the conference and other events, as Exhibit 99.1 to this Report and such PowerPoint is incorporated herein by reference; the presentation will also be available on the Company’s website www.aptorumgroup.com.

 

Neither this report nor the presentation attached hereto as Exhibit 99.1 constitute an offer to sell, or the solicitation of an offer to buy our securities, nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

 

The information in this Form 6-K, including Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

EXHIBIT LIST

Exhibit		Description
99.1		PowerPoint Presentation

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 4, 2019

 

	Aptorum Group Limited
	By:	/s/ Ian Huen
		Ian Huen
		Chief Executive Officer and Executive Director

 

Exhibit 99.1

 

 

OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS Corporate Presentation NASDAQ Global Market: APM 1

© Copyright 2019 Aptorum GroupLimited Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the “Company”) are not historical facts but are forward - looking statements. These forward - looking statements refer in particular to the Company’s management’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements . Forward - looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward - looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice . Such forward looking statements are for illustrative purposes only . Forward - looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company . These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post - marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates . A detailed description of risks and uncertainties related to the Company’s activities is included under the “Risk factors” section of the Company’s Prospectus (File No . 333 - 227198 ) filed with the Securities and Exchange Commission on December 4 , 2018 and is available on the Company’s website (www . aptorumgroup . com) . This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company’s business and markets . Such information is based on the Company’s analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports . The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts . Such data and forecasts are included in this presentation for information purposes only . This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in the United States or any other jurisdiction . This presentation includes only summary information and does not purport to be comprehensive . No reliance should be placed on the accuracy or completeness of the information or opinions contained in this presentation . DI SCLA IMER 2

A) Aptorum Group (Nasdaq: APM) is a Hong Kong based biopharmaceutical company currently with market capitalization over USD400m; B) Ma n agem e n t a n d b oar d o f d i rec t ors w i t h d ive r s e b a c k groun d and accomplishments in finance, healthcare industry; C) 12 technologies (from 11 exclusive licenses) under development D) Non - antibiotic approach intended for the treatment of infections caused by MRSA of gut microbiota metabolites for the treatment of various E) Modulation diseases. APTORUM SUMMARY © Copyright 2019 Aptorum GroupLimited For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. 3

MR. IAN HUEN Founder, Chief Executive Officer and Executive Director MR. DARREN LUI President, Chief Business Officer and Executive Director DR. CLARK CHENG Chief Medical Officer and Executive Director • Over 15 years in global asset management • US healthcare equity research analyst at Janus Henderson Group • Trustee board member of Dr. Stanley Ho Medical Development Foundation • CFA, Princeton University (Econ) • Over 13 years in global capital market • Extensive exposure in UK, Singapore, US. • ICAS, CFA & Associate of Chartered Institute of Securities & Investments (UK) • First - Class Honors from Imperial College (Biochemistry) • Almost 10 years working in Raffles Medical Group as Operations Director and Deputy General Manager • Received medical training at the University College London in 2005 & obtained membership of the Royal College of Surgeons of Edinburgh in 2009 • MBA, University of Iowa MISS SABRINA KHAN Chief Financial Officer DR. THOMAS LEE WAI YIP • Almost 10 years serving US & Asian healthcare companies • Extensive experience in business development, restructuring, US & Asian IPO, and M&A deals • Solid accounting experience gained from Big 4 • Advanced China Certified Taxation Consultant • CPA, the University of Hong Kong (BBA(Acc & Fin)) Chief Executive Officer & Chief Scientific Officer - Aptorum Therapeutics Limited • Former Assistant Professor at The Chinese University of Hong Kong (CUHK) specialized in drug delivery and formulation development • 10 years working at Novartis & Celgene • B.Pharm.(Hons), CUHK; Ph.D. in Pharmaceutical Sciences (Drug Delivery), the University of Wisconsin - Madison LEADERSH I P © Copyright 2019 Aptorum GroupLimited 4

PROJECT PORTFOLIO DRUG AND DEVICE CANDIDATES PROJECTS CANDIDATE / MODALITY INDICATION DEVELOPMENT STAGE Target I de nt i f i cat i on & Selection Lead D i sc o ve r y Lead Op ti m i za ti o n IND - Enabling Phase 1 Phase 2 Phase 3 VIDENS’ SERIES VLS - 1 Curcumin - MNP (Medical Imaging Agent for MRI Diagnosis) Diagnosis of Alzheimer’s Disease VLS - 2 MITA (mTor - independent TFEB activator) Treatment of Alzheimer’s & Parkinson’s Disease VLS - 3 Non - Invasive Retina Imaging Diagnostics Diagnosis of Alzheimer’s Disease VLS - 4 Imaging Agent for MRI Diagnosis Diagnosis of Alzheimer’s Disease ACTICULE’S SERIES ALS - 1 Small Molecule Treatment of viral infections caused by Influenza virus A ALS - 2 Small Molecule Treatment of bacterial infections caused by Staphylococcus aureus including MRSA ALS - 3 Small Molecule Reviving existing antibiotics to overcome drug resistance ALS - 4 Small Molecule Treatment of bacterial infections caused by Staphylococcus aureus including MRSA Lead Projects Other Candidates Device Candidates 5 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

PROJECT PORTFOLIO PROJECTS CANDIDATE / MODALITY INDICATION DEVELOPMENT STAGE Target I de nt i f i cat i on & Selection Lead D i sc o ve r y Lead Op ti m i za ti o n IND - Enabling Phase 1 Phase 2 Phase 3 NATIVUS’ SERIES NLS - 1 Small molecule Treatment of Endometriosis NLS - 2 An extract from Chinese yam Relief of Menopausal Symptoms NLS - 3 SAC Treatment of and protection against retinal ischemia/ reperfusion injury SCIPIO’S SERIES SPLS - 1 83b - 1 Novel Quinoline Derivative Treatment of liver cancer PROJECTS CANDIDATE / MODALITY INDICATION DEVELOPMENT STAGE Lab - based Phantom Trial A n i mal Trial IDE Application Approval S a fe t y / F es i b ili t y Clinical Study Pivotal Clinical Study Process of obtaining PMA SIGNATE’S SERIES SLS - 1 Robotic catheter platform for Intra - operative MRI - guided cardiac catheterization Heart rhythm disorders by cardiac electrophysiology intervention On - going Lead Projects Other Candidates Device Candidates 6 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited OTHER KEY PROJECTS ALS - DDC Drug Discovery Center + Chemical Library Drug discovery by identification and screening of drug molecules for various indications Setting Up AML Clinic Clinic - Talem Medical Medical Services Commenced operations in June 2018

OVERVIEW OF OUR LEAD PROJECTS ALS - 1 INFLUENZA A ALS - 4 STAPHYLOCOCCUS INCLUDING METHICILLIN - RESISTANT S. AUREUS (MRSA) NLS - 1 ENDOMETRIOSIS Population affected: Annual epidemics estimated to result in ~ 3 - 5 million cases of serious influenza infections, causing about 290 , 000 - 650 , 000 deaths each year i , around 50 - 80 % of influenza infections are type A ii . Population affected: 53 million people worldwide carry MRSA i . For example, in U.S., ~126,000 hospitalizations are due to MRSA yearly, where severe infections occur in ~94,000 people each year and are associated with ~19,000 deaths ii . Population affected: ~176 million women globally (  1 in 10 women during their reproductive years) i . ~30 - 40% of women with endometriosis are subject to risk of infertility and may develop complications during pregnancy ii . Market Size: Global Market Size in 2016: US$ 0.60 billion iii . Expected Global Market Size by 2025: US$ 1.2billion iii . Market Size: Global Market Size in 2016: US$ 2.97 billion iii . Expected Global Market Size by 2025: US$ 3.91 billion iii . Market Size: Market Size in 2015: US$ 1.72 billion (across the 7 major countries) iii . Expected Market Size by 2025: just over US$ 2 billion (across the 7 major countries) iii . i. WHO: Influenza (Seasonal), http://www.who.int/en/news - room/fact - sheets/detail/influenza - (seasonal) ii. WHO Global circulation of influenza viruses, http://apps.who.int/flumart/Default?ReportNo=6 iii. Bloomberg: New Drugs Are Coming to Fight Nasty Flu Seasons (9 Feb 2018), https://www.bloomberg.com/news/articles/2018 - 02 - 08/flu - relief - is - coming - as - successors - to - aging - tamiflu - near - marke t i. Roche Annual report 2017, https://www.roche.com/dam/jcr:78519d71 - 10af - 4e02 - b490 - 7b4648a5edb8/en/ar17e.pd f ii. emedicinehealth: MRSA https://www.emedicinehealth.com/mrsa_infection/article_em.htm#how_common_is _mrsa iii. Healthcare Drive: Global Methicillin - resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast Predictions, https://www.healthcaredive.com/press - release/20180405 - global - methicillin - resistant - staphylococcus - aureus - mrsa - drugs - market - anal/ 7 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited i.Endometriosis.org: Facts about endometriosis, http://endometriosis.org/resources/articles/facts - about - endometriosis/ ii.Washington University Physicians, “Endometriosis”, https://fertility.wustl.edu/getting - started - infertility/infertility - factors/endometriosis/ J. Fisher M. Kirkman, “Endometriosis and fertility: women’s accounts of healthcare”, Human Reproduction, Volume 31, Issue 3, March 1, 2016, Pages 554 – 562, January 11, 2016, https://doi.org/10.1093/humrep/dev337 iii. R&D: Endometriosis Market Expected to Surpass $2 Billion by 2025 (11 Nov 2016) – By Global Data. List of 7 major countries: the US, France, Germany, Italy, Spain, the UK and Japan, https://www.rdmag.com/news/2016/11/endometriosis - market - expected - surpass - 2 - billion - 2025

ALS - 4 8 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Treatment of Bacterial Infections including MRSA by a Non - antibiotic Approach

ALS - 4 Inflammation C a p sule Inhibit phagocytosis • Bacterial infections are mediated by pathogenic or opportunistic bacteria • Successful infections depends on host’s immunity and pathogen’s virulence • Targeting bacterial virulence is an alternative approach to antimicrobial therapy 9 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited The figure is modified from Rachel J. Gordon, et al. Clin Infect Dis. (2008)

ALS - 4: THE ADVANTAGE OF TARGETING VIRULENCE EXPRESSION - DISARMING THE BACTERIA • Antibiotics are usually broad spectrum and indiscriminate • Commonly affect normal flora, may lead to super - infection in case of drug resistance Antibiotics Non - antibiotics A n tibiotics Non - antibiotics • Not bactericidal, no selective pressure to promote drug resistance • Pathogen specific, avoid normal flora casualties • Only reduce pathogenicity of bacteria, bacterial clearing is mediated by host immunity x Avoid Bacterial Drug Resistance x Preserve Host Normal Flora In disc r i min a t e clearance 10 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Directed against pathogen 1. Köhler T, Perron GG, Buckling A, van Delden C. PLoS Pathog.2010 May 6;6(5):e1000883. 2. Yu X - Q, Robbie G J, Wu Y, Esser M T, Jensen K, Schwartz H I, Bellamy T, Hernandez - Illas M, Jafri H S. Antimicrob Agents Chemother. 2017;61:e01020 – 16. 3. Milla C E, Chmiel J F, Accurso F J, VanDevanter D R, Konstan M W, Yarranton G, Geller D E. Pediatr Pulmonol. 2014;49:650 – 658. 4. DiGiandomenico A, Keller A E, Gao C, Rainey G J, Warrener P, Camara M M, Bonnell J, Fleming R, Bezabeh B, Dimasi N, et al. Sci Transl Med. 2014;6:262r. S o u r c es

THE MECHANISMS OF ALS - 4 - ANTI - GOLDEN PIGMENT AGENT mBio (8(5): e01224, 2017)) • Staphyloxanthin is the golden yellow pigment of S. aureus • The pigment protects the bacteria against oxidative stress produced by our immune cells. • ALS - 4 is intended to suppress one of the key enzymes in the pigment production process • S. aureus without pigments are more susceptible to host immune clearance Pigment formation ALS - 4 Absence of golden color 11 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

in vivo AND in vitro EFFICACY OF ALS - 4 - PRELIMINARY ANIMAL SAFETY ALS - 4 is intended to inhibit S. aureus pigment production with an IC 50 = 20nM DMSO Control ALS - 4 200 nM 100 nM 50 nM 25 nM 12.5 nM 6.25 nM 3.13 nM ALS - 4 is observed to reduce bacterial load in mice C F U /K id n e y in lo g s c a le 0 2 4 6 8 * C F U /K id n e y in lo g s c a le 0 2 4 6 8 Acute treatment Compound concentration: 1 mM; Inoculum: 5 X 10 6 per mouse Treatment: twice for first 7 days, First inject: 30 min after infection Delayed treatment Compound concentration: 1 mM; Inoculum: 2 X 10 7 per mouse Treatment: twice for 7 days, First inject: 11 days after infection 12 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

MECHANISM OF ALS - 2 AND ALS - 3 ALS - 2 is being developed to reduce virulence gene production ALS - 2 is intended to inhibit ClpP ALS - 2 is shown to rescue mice from S. aureus infection ADAPTED FROM: doi : 1 0. 1 073/ pna s . 1 720520 1 1 5 ALS - 3: An antibiotic - potentiating compound by using a non - antibiotic approach 13 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

AWARD WINNING CONCEPT AT ICPIC IN GENEVA, 2017 - NON - ANTIBIOTICS ANTI - VIRULENCE APPROACH This is the first time chemical genetics have been applied in an attempt to tackle MRSA infection . This revolutionary concept and discovery of the applications of chemical genetics, which forms the basis of the discovery of ALS - 2 , ALS - 3 and ALS - 4 , has been highly praised at the 4 th International Conference on Prevention & Infection Control (ICPIC 2017 ) in Geneva, Switzerland . The Company’s Hong Kong team, led by Dr . Richard KAO, won First Place in the Innovation Academy category at the conference . 14 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

ALS - 4 15 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Preclinical Findings • MRSA has developed resistance to many, if not all, of the existing drugs available for treatment. • ALS - 4 employs a non - antibiotic approach designed to act on a unique therapeutic target to inhibit production of staphyloxanthin, which distinguishes it from other current treatments. • Studies have shown that staphyloxanthin is an important factor in enabling MRSA bacteria to escape from the immune system. • ALS - 4 has been developed to inhibit production of staphyloxanthin without killing the bacteria, which should enable the immune system to clear MRSA. • Current Development Status: Lead Optimization and Ph 1 and in preparation for IND filing. Ph 1 clinical trial is expected to commence in 2020. • ALS - 2 and ALS - 3, which also employ a non - antibiotic approach for the intended treatment of bacterial infections, are currently under active development and are at Lead Optimization stage.

ALS - 1 16 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Treatment of Infections caused by Influenza A Viruses via a Unique Therapeutic Target

ALS - 1 • ALS - 1 acts on a unique therapeutic target, nucleoproteins, which distinguishes it from all other currently marketed antiviral drugs which currently experience resistance from Influenza A virus. • Inhibition of virus replication in vitro and outperforms oseltamivir (Tamiflu®) with a lower IC50 (half maximal effective concentration). • Animal studies suggest that ALS - 1 has the potential to be developed into a useful anti - influenza therapeutic. • Current Development Status: Lead Optimization and in preparation for IND filing by 2020/2021 PFU relative to controls in the absence of compounds (%) Concentration of compounds ( µM ) H1N1 (A/WS N/33) with nucleozin H3N2 (clinical isolate) with nucleozin H5N1 (A/Vietnam/1 194/04) with nucleozin H1N1 (A/WS N/33) with oseltamivir PFU/ml This figure shows the concentration dependence of ALS - 1 in reducing the plaque - forming unit (pfu, a measure of number of infectious virus particulates, which represents the in vitro efficacy of the drug) of human H 1 N 1 , H 3 N 2 and H 5 N 1 influenza viruses . The IC 50 (the concentration of drug at which 50 % of the virus is inhibited) for these viruses is between 0 . 1 - 1 µM . Oseltamivir (curve in red) is included for comparison in terms of in vitro efficacy against H 1 N 1 . The curve of ALS - 1 is in the left side of the red curve, indicating ALS - 1 has a lower IC 50 . 17 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited This figure shows that MDCK cells were infected and ALS - 1 (1 μM) was added before infection (− 1 h), at the time of infection ( 0 h) and at 1 , 2 , 4 , 6 and 8 hour after infection as indicated . + = a control without ALS - 1 . This figure indicates that ALS - 1 inhibited viral growth even when added within 6 hours after inoculation of the MDCK cells with the virus, indicating that the antiviral activities of ALS - 1 reside on post - entry and post - nuclear events, suggesting that multiple processes involving NP may be affected . (Adapted from Nature Biotechnology (28 (6): 600, 2010)) (Adapted from Nature Biotechnology (28 (6): 600, 2010))

NLS - 1 18 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Treatment of Endometriosis by a Non - hormonal Approach

Endometrium outside the uterine cavity A chronic gynecological disorder affecting 10% of woman during reproductive ages with 176 million known cases worldwide i Medical Problem chronic pelvic pain/dysmenorrhea Infertility ectopic pregnancy/ miscarriage E NDO M E T R IOS I S 19 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited i.Endometriosis.org: Facts about endometriosis, http://endometriosis.org/resources/articles/facts - about - endometriosis/

PA T HO P HYSIO LOGY 20 ectopic endometrial cells proliferating endometrial cells surviving endometrial cells Adhesion Proliferation Angiogenesis immune c l ea r ance Peritoneal lining (ovary, oviduct, ligaments, bowels, etc) The figure is modified from Human Reproduction Update, Vol.17, No.6 pp. 829 – 847, 2011

Possible hormonal side - effects Med ici ne Surgery Current Treatment for Endometriosis 21 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Potential recurrence

NLS - 1 Studies utilizing mouse endometriosis models demonstrated that administration of NLS - 1 resulted in greater reductions in the size and weight of lesions than Vitamin E, EGCG or the control without any treatment molecule . St u d ies util i z i n g m ouse en d ometrios is m o d els demonstrated that administration of NLS - 1 resulted in greater reductions in angiogenesis than Vitamin E, EGCG or the control without any treatment molecule. S a l in e In Situ Sections pro - EGCG EG CG Vitamin E Sal i n e E G C G 1 2 1 0 8 6 4 2 0 Vitamin E pro - E GC G lesion size (mm3) lesion weight (mg) S a l in e C e ll v iz i o µ CT CD31/ α SMA pro - EGCG EG CG Vitamin E 22 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited (Adapted from Angiogenesis (16:59, 2013)) (Adapted from Angiogenesis (16:59, 2013))

Prevention Treatment S a li ne EGCG pro - ECCG Sa li ne E GCG p r o - E GCG PROPHYLACTICS & THERAPEUTICS 23 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Data generated by Prof. Wang, Chi Chiu Ronald, Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong

EFFICACY IN AN ANIMAL MODEL NLS - 1 (Pro - EGCG at different doses and dosing schedule) 24 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited Comparison of the efficacy of different treatment in an experimental endometriosis model

Angiogenesis 2013b NLS - 1 General & Reproductive Safety 25 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2019 Aptorum GroupLimited

NLS - 1 Preclinical Findings • Drug molecule derived from EGCG which is extracted from green tea. • Intended as non - hormonal treatment for endometriosis. • Studies in animal models show reductions in development, growth and angiogenesis of endometriosis greater than EGCG. • Our treatment may provide an alternative to hormonal treatments which typically have undesirable side effects. • Current Development Status: Lead Optimization and in preparation of IND filing by 2020/2021. For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. 26

A pp e n d i x 27

SELECTED INCOME STATEMENT SUMMARY (US GAAP) Ten months ended December 31, 2017 Six months ended June 30, 2018 U S $ U S $ Healthcare services income - 26,662 Costs of healthcare services - 22, 7 49 Research and development expenses 2,560,323 1,34 2 ,179 General and administrative fees 1,480,093 2,23 8 ,0 2 5 Legal and professional fees 1,39 5 ,490 1,063,032 Other operating expenses 2 5 7 , 1 7 7 23 5 ,413 Total operating expense 5,69 3 ,0 8 3 4,901,398 Other income (loss) 3,1 3 1, 5 7 6 - 661,206 Net loss attributable to the Company's shar eholder s - 2,547,462 - 5,488,372 Depreciation and amortisation 5 8 ,903 209, 2 67 SELECTED BALANCE SHEET ITEMS (US GAAP) December 31, 2017 June 30, 2018 US $ U S $ Cash and restricted cash 16,725,8 0 7 22,9 2 7 ,198 Total current assets 20, 2 8 3 ,399 26,3 7 1,722 Property, plant and equipment, net 346,5 8 7 4, 2 1 1,321 Intangible assets, net 1 , 4 7 2,707 1,452,486 Total assets 3 1 ,559, 9 82 41,465,225 Convertible debts 480,000 15,6 8 7 , 8 4 7 Total current liabilities 1,3 3 0, 7 34 16,7 8 3,6 4 1 Total liabilities 1,3 3 0, 7 34 16,949, 7 78 Total shareholders' equity 30,229, 2 48 2 4,51 5 , 4 4 7 Working capital* 1 8 ,952,665 9,5 8 8, 0 81 * Total current assets less total current liabilities FINANCIAL OVERVIEW The above financials are extracted based on audited accounts for the ten months ended December 31, 2017 and unaudited accounts for the six months ended June 30, 2018. Past performance is not indicative of future results. 28 © Copyright 2019 Aptorum GroupLimited

FINANCIAL OVERVIEW (US$) ROUNDED TO THE NEAREST THOUSAND Cash and restricted cash, and marketable securities US$18,698,000 (as of 12/31/2017) US$25,022,000 (as of 6/30/2018) Intangible assets, net US$1,473,000 (as of 12/31/2017) US$1,452,000 (as of 6/30/2018) Operating expenses US$5,693,000 (ten months ended 12/31/2017) US$4,901,000 (six months ended 6/30/2018) Convertible debts US$480,000 (as of 12/31/2017) US$15,688,000 (as of 6/30/2018) 2018 MAY 2018 APRIL 20 1 7 CAPITAL RAISED IN THE PAST 12 MONTHS Series A Equity Financing of US$8.6m Series A Note Offering of US$1.6m US$15m Convertible Bond issued to Peace Range Limited, a SPV of Adamas Ping An Opportunities Fund L.P. The above financials are extracted based on audited accounts for the ten months ended December 31, 2017 and unaudited accounts for the six months ended June 30, 2018. Past performance is not indicative of future results. 29 © Copyright 2019 Aptorum GroupLimited

IP STATUS OF ALS - 1 30 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Exclusively licensed Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Antiviral Compounds And Methods Of Making And Using Thereof US 9212177 (App. No. 12/850,806) 2011/0212975 5 Aug 2010 27 Nov 2031 Granted Antiviral Compounds And Methods Of Making And Using Thereof China 201080044361.6 102596946B 5 Aug 2010 5 Aug 2030 Granted Antiviral Compounds And Methods Of Making Europe 2462138 (App. No. 10805941 . 1) n/a 5 Aug 2010 5 Aug 2030 Granted Antiviral Compounds And Methods Of Making Germany 60 2010 019 171.0 n/a 5 Aug 2010 5 Aug 2030 Granted AL S - 1

IP STATUS OF ALS - 2 and ALS - 3 31 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Exclusively licensed Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Antimicrobial US App. No Not yet published 13 Dec 2018 n/a Pending Compounds And 16/309,516 Methods For Use Thereof Antimicrobial Europe App. No Not yet published 12 Dec 2018 n/a Pending Compounds And 17812663.7 Methods For Use Thereof Antimicrobial Malaysia App. No Not yet published 12 Dec 2018 n/a Pending Compounds And 2018002512 Methods For Use Thereof Antimicrobial Singapore App. No Not yet published 12 Dec 2018 n/a Pending Compounds And 11201811093R Methods For Use Thereof ALS - 2,3

IP STATUS OF ALS - 2 and ALS - 3 32 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Exclusively licensed Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Antimicrobial Compounds And Methods For Use Thereof China App. No 201780035312 . 8 Not yet published 6 Dec 2018 n/a Pending Antimicrobial Compounds And Methods For Use Thereof Indonesia App. No PID 2 01900183 Not yet published 9 Jan 2019 n/a Pending Antimicrobial Compounds And Methods For Use Thereof India App. No 201927001415 Not yet published 11 Jan 2019 n/a Pending Antimicrobial Compounds And Methods For Use Thereof Japan App. No 2018 - 565820 Not yet published 14 Dec 2018 n/a Pending Antimicrobial Compounds And Methods For Use Thereof Korea 10 - 2019 - 7001227 Not yet published 14 Jan 2019 n/a Pending ALS - 2,3 cont’d

IP STATUS OF ALS - 4 33 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Exclusively licensed Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Compounds And US App. No Not yet published 22 Jul 2018 n/a Pending Methods For The 16/041,836 Treatment Of Microbial Infections Compounds Affecting US App. No Not yet published 23 Jul 2018 n/a Pending Pigment Production 16/041,838 And Methods For Treatment Of Bacterial Diseases AL S - 4

IP STATUS OF NLS - 1 34 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. Technology 1 – Compound (Exclusively licensed) Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Epigallocatechin gallate derivatives for inhibiting proteasome US 7544816 (App. No. 10/921,332) US2006/0041010 19 Aug 2004 3 Oct 2025 Granted Same as above US 8193377 (App. No. 11/660,513) US2008/0176931 15 Aug 2005 26 Nov 2026 Granted Same as above US 8710248 (App. No. 13/416,657) US2012/0232135 9 Mar 2012 15 Aug 2024 Granted Same as above US 9169230 (App. No. 14/229,315) US2014/0213802 28 Mar 2014 15 Aug 2024 Granted Same as above China 200580035478.7 CN101072764B 15 Aug 2005 15 Aug 2025 Granted Same as above Europe 1778663 (App. No. 05779886) n/a 15 Aug 2005 15 Aug 2025 Granted Same as above India 263365 (App. No. 603/KOLNP/2007) n/a 19 Feb 2007 15 Aug 2025 Granted Same as above Japan 5265915 (App. No. P200 7 - 526180) P2008 - 509939A 15 Aug 2005 15 Aug 2025 Granted NL S - 1

IP STATUS OF NLS - 1 35 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. NLS - 1 c on t ’ d Technology 2 – Indication for treatment of endodermises (Exclusively licensed) Title Country Application No. / Patent No. Publication No. / Grant Publication No. Application Date Expiration date Status Prodrug of green tea epigallocatechin - 3 - gallate (Pro - EGCG) for use in the treatment of endometriosis US 9713603 (App. No. 14/422,642) 2015/0216841 20 Aug 2013 20 Aug 2033 Granted Same as above US 10188629 (App. No. 15/628,001) 2017/0281591 20 Jun 2017 20 Aug 2033 Granted Same as above US App. No 16/259,620 n/a 28 Jan 2019 n/a Pending Same as above China 201380052717.4 104703596A 10 June 2015 n/a Pending Same as above Hong Kong 15111955.3 1210971 3 Dec 2015 n/a Pending

PROFESSOR DOUGLAS ARNER Independent Non - Executive Director Kerry Holdings Professor in Law, HKU DR. JUSTIN WU Independent Non - Executive Director Chief Operating Officer, CUHK Medical Centre DR. MIRKO SCHERER Independent Non - Executive Director CEO of TVM Capital China MR. CHARLES BATHURST Independent Non - Executive Director Founder of Summerhill Advisors Limited DR. NISHANT AGRAWAL Senior Clinical Advisor Professor of Surgery, School of Medicine, University of Chicago DR. HENRY CHAN LIK YUEN Senior Advisor Associate Dean, Faculty of Medicine, CUHK DR. PHILIP W.Y. CHIU Senior Advisor Professor, Department of Surgery, Institute of Digestive Disease, CUHK DR. VINCENT MOK CHUNG TONG Senior Advisor Head of Division of Neurology, Dept of Medicine & Therapeutics, CUHK DR. KENNY YU KWOK HEI DR. KA - WAI KWOK DR. JASON Y. K. CHAN DR. OWEN KO HO DR. WAI - LUNG NG DR. SUNNY WONG HEI DR. WILLIAM WU KA KEI Scientific Assessment Scientific Assessment Scientific Assessment Scientific Assessment Scientific Assessment Scientific Assessment Scientific Assessment Committee Member Committee Member Committee Member Committee Member Committee Member Committee Member Committee Member NIHR Academic Clinical Assistant Professor, Assistant Professor, Assistant Professor, Research fellow, Dana - Assistant Professor, Associate Professor, Lecturer, the University Department of Mechanical Department of Department of Medicine Farber Cancer Institute/ Department of Medicine Department of of Manchester Engineering, the University of Hong Kong Otorhinolaryngology, CUHK and Therapeutics, CUHK Harvard Medical School and Therapeutics, CUHK Anaesthesia and Intensive Care, CUHK INDEPENDENT NON - EXECUTIVE DIRECTORS SCIENTIFIC ADVISORS 36 © Copyright 2019 Aptorum GroupLimited